CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
taurinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01192828
NCT01192828Phase 2Completed

Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

University of Colorado, Denver·interventional·Posted Sep 1, 2010·Updated Jul 9, 2018

In Brief

A Phase 2 clinical trial evaluating taurine for Homocystinuria. Completed, enrolled 15 participants across 4 sites.

Detailed Summary

Cystathionine beta-synthase deficiency is an inherited disease that results in elevation of a substance called homocysteine (Hcy) in blood and urine. Individuals with this disorder have a very high risk for developing blood clots and are at risk for developing eye and bone abnormalities. Current treatments are generally difficult to follow and can fail. Development of additional therapies has been limited by lack of understanding of how the disease works. The purpose of this study is to see if oxidative stress and inflammation are involved in the disease process and if short-term supplementation with taurine is an effective treatment. Funding source: FDA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHomocystinuria
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 1, 2010
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 15.8 years ago

Interventions

taurinedrug

Take Taurine for 4 1/2 days, two doses per day